Dec 24 2010
Accuray has declared that it has received the U.S. Food and Drug Administration’s (FDA) 510(k) approval for Lung Optimized Treatment, a new tool of the CyberKnife VSI System. This approval enables the company to offer surgeons with improved adaptability in offering radiosurgery therapy for lung cancer patients.
Recent investigations have determined that radiosurgery is an ideal therapy option for clinically untreatable lung cancer victims, as it offers enhanced local control and improved turnover rates. Treating lung cancer is highly difficult due to the nearness of the tumor to vital organs and tissues of the respiratory system. Lung Optimized Treatment provides required precision and sudden dosage drop for efficiently treating lung tumors, even if they are very near to vital tissues. Simulation and comparison workflows linked with novel tracing modes enable the surgeon to choose from several minimally-invasive choices, irrespective of the location of the tumor.
Chris A. Raanes, Senior Vice President and Chief Operating Officer for Accuray, has stated that Lung Optimized Treatment is a new component developed to cope with the clinical requirements for more adaptability in treating lung cancer using radiosurgery. He has mentioned that the new technology also replaces fiducial implantation, eliminating the high risk of pneumothorax. He added that the new method treats lung cancer without any incision.
According to Euan S. Thomson, President and Chief Executive Officer of Accuray, with the new approval they have enabled this therapy for a wide group of lung cancer patients. He added that the approval has depicted their initiatives in assuring that surgeons have improved access to therapy options required for their patients.